SGRY

In the past six months (April to October 2026), Surgery Partners, Inc. (SGRY) stock increased by 6.6%, despite a 34.20% decline over the past year (September 2025 to September 2026), trading between $11.41 and $23.25 over the past 52 weeks. The company reported a Q1 2026 loss of $35.9 million, or 3 cents per share, beating Wall Street estimates, with revenue of $810.9 million also surpassing expectations. Q2 2026 results showed revenue increasing 2.7% year-over-year to $848.9 million and adjusted EPS of $0.10, both exceeding analyst expectations, while the company reaffirmed its full-year guidance. Surgery Partners agreed to sell its Idaho Falls facilities to Intermountain Health, completing the sale by September 17, 2026, a strategic move for portfolio optimization that was viewed positively by analysts. Several directors purchased shares valued at approximately $160,000 each in June 2026, signaling insider confidence. As of October 2026, analysts have a 'Moderate Buy' consensus rating with an average price target of $19.00, suggesting a potential 39.3% upside.